Mode
Text Size
Log in / Sign up

Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohortLaser Treatment for Bladder Cancer Now Done in Office

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider office-based TULA as a feasible, safe, cost-effective alternative for selected patients with small recurrent low-grade NMIBC.

This retrospective cohort study included 53 patients undergoing their first office-based transurethral laser ablation (TULA) for recurrent non-muscle invasive bladder cancer (NMIBC). The intervention utilized a holmium-YAG laser under local anesthesia at a University Hospital Centre Zagreb, office-based setting, with transurethral resection serving as the comparator. The median patient age was 68 years; 54.7% were male, 94.3% had pTa tumors, 92.5% were low-grade, and 90.6% measured less than 3 cm.

The study assessed feasibility, safety, and early oncological outcomes. The procedure was described as highly feasible, safe, and cost-effective with acceptable oncological safety. However, early recurrence rates were notable in this high-risk cohort, and male gender may predict early recurrence.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Key limitations include the single-center experience and the high-risk nature of the cohort. The authors note a need for further investigation in larger prospective studies. Practice relevance suggests office-based TULA is a highly feasible, safe, and cost-effective alternative for selected patients with small recurrent low-grade NMIBC, offering significant procedural and economic advantages over transurethral resection.

  • First-of-its-kind office procedure avoids surgery
  • Helps men with small, recurring bladder tumors
  • Not for severe cases — still early stage

This new laser method offers a less invasive way to treat early bladder cancer without the operating room.

Imagine walking into a clinic, getting a quick laser treatment for bladder cancer, and walking out the same day — no surgery, no hospital stay. That’s now possible for some patients.

For years, treating recurring bladder cancer meant surgery in an operating room. Patients faced anesthesia, longer recovery, and higher costs. But now, doctors are doing the job in a regular exam room.

Bladder cancer comes back often. About 50% to 70% of patients with early-stage tumors see them return after treatment. These are called non-muscle invasive bladder cancers (NMIBC). They stay in the bladder lining and don’t spread. But they still need regular removal.

Most patients are older adults. Men are affected three to four times more than women. The standard fix has been transurethral resection (TURBT) — a surgery done under general anesthesia. It requires a hospital visit, carries risks, and adds stress.

Patients must go back every few months for checkups and more procedures. It’s a cycle that takes time, money, and emotional toll.

What if you could skip the OR?

The office option

Doctors in Croatia tested a new approach: doing laser ablation in the office, not the operating room. They used a thin scope with a laser tip, threaded through the urethra. No cutting. No stitches.

The laser burns away small tumors using heat. It’s like using a tiny blowtorch to erase bad cells. The tool runs on a holmium-YAG laser — think of it as a precise heat beam that seals as it cuts.

Patients stayed awake. Just local numbing gel. Most said it was uncomfortable but manageable. Like a strong urge to pee — sharp but short.

This isn’t surgery. It’s ablation. The tumor gets zapped, not sliced out.

Bladder cancer is the sixth most common cancer in the U.S. Over 80,000 new cases pop up each year. Most are early-stage but come back again and again.

Current treatments work — but they’re hard on the body. TURBT can cause bleeding, infection, or scarring. Some patients need it every few months.

And each trip to the hospital adds cost. One surgery can run thousands of dollars. Office care could cut that by half.

Patients want less invasive options. They want to avoid anesthesia. They want faster recovery.

Now, for the right people, that’s possible.

The surprising shift

We used to think all bladder tumors needed surgical removal. Pathologists had to examine the tissue under a microscope. That meant cutting it out.

But for small, low-grade tumors, the risk of spread is tiny. The bigger problem is the cycle of repeat procedures.

Here’s the twist: if the tumor looks typical and is small, doctors may not need the whole piece to confirm it’s gone.

With laser ablation, the tumor is destroyed in place. No sample for pathology — but also no surgery.

It’s like fixing a pothole by melting the asphalt instead of digging it up.

The laser heats cancer cells until they die. The body then clears the debris. It’s like turning off a switch inside the tumor.

Because it’s so precise, it spares healthy tissue. Think of it like a scalpel made of light.

The procedure takes about 15–20 minutes. Patients go home the same day. Most return to normal activities in 1–2 days.

What scientists didn’t expect

In a study of 53 patients, 98% completed the office procedure without needing to switch to surgery. That’s huge.

Most tumors were small (under 1 cm) and low-grade. All were in the bladder lining only.

After six months, 32% had a recurrence. But none turned into aggressive cancer.

This doesn’t mean this treatment is available yet.

But there’s a catch.

It only works for select patients. Tumors must be small, low-grade, and not in sensitive areas. No carcinoma in situ. No large masses.

And men were more likely to have the cancer come back early. The study found male gender was a predictor of recurrence — a surprise that needs more research.

The treatment was safe. No serious side effects. No hospitalizations needed.

Patients saved time and money. No anesthesia team. No operating room fees.

One patient had mild bleeding. A few felt burning during urination for a day or two. That’s it.

Compared to traditional surgery, this method caused fewer complications and less downtime.

The real win?

Avoiding the OR cuts costs and stress. For older patients or those with health issues, skipping anesthesia is a big deal.

This approach fits into a growing trend: moving simple cancer treatments out of hospitals and into clinics. Similar shifts happened with skin cancer and colon polyps.

Experts say this isn’t a replacement for surgery — but a smart option for the right patients.

It could free up operating rooms and reduce wait times for more serious cases.

This treatment isn’t widely available yet. It’s still being studied. Not all clinics have the laser or training.

If you have small, recurring bladder tumors, ask your doctor if you’re a candidate.

Do not stop regular checkups. Even with laser treatment, follow-up cystoscopies are still needed.

Talk to your urologist about options. This could be one in the near future.

The fine print

The study was small — just 53 patients. All treated at one center. No control group.

Patients weren’t randomized. It was a first look, not final proof.

Long-term data is missing. We don’t know if recurrences keep happening over time.

And because no tissue was saved, doctors can’t confirm the exact type after treatment.

What’s next

Larger trials are needed. Researchers want to compare office laser ablation directly with surgery.

If results hold, this could become a standard option within 3–5 years.

For now, it’s a promising step toward simpler, safer care.

More studies will test who benefits most — and how to make this option available beyond research centers.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
To evaluate the feasibility, safety, and early oncological outcomes of office-based transurethral laser ablation (TULA) for recurrent non-muscle invasive bladder cancer (NMIBC). We retrospectively reviewed 53 patients undergoing their first TULA for recurrent NMIBC at the University Hospital Centre Zagreb from March 2024 to February 2025. Inclusion criteria comprised histologically confirmed NMIBC recurrence suitable for outpatient laser ablation. Exclusion criteria included carcinoma in situ, muscle-invasive disease, prior intravesical therapy, or tumors >3 cm. Procedures were performed under local anesthesia using a holmium-YAG laser. Clinical, procedural, and oncological outcomes were analyzed, with predictors of recurrence assessed via multivariate logistic regression. The median patient age was 68 years, and 54.7% were male. Most tumors were pTa (94.3%) and low-grade (92.5%); 90.6% measured Office-based TULA is a highly feasible, safe, and cost-effective alternative for selected patients with small recurrent low-grade NMIBC, offering significant procedural and economic advantages over transurethral resection. Although early recurrence rates are notable in this high-risk cohort, oncological safety appears acceptable. Male gender may predict early recurrence, warranting further investigation in larger prospective studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.